Objective Etanercept has been shown to improve the articular and cutaneous manifestations
of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect …

Objective To develop simple, practical criteria for clinical diagnosis of fibromyalgia that are
suitable for use in primary and specialty care and that do not require a tender point …

Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was
evaluated for its safety and efficacy compared with placebo in the treatment of active …

Objective. To compare the accuracy of existing classification criteria for the diagnosis of
psoriatic arthritis (PsA) and to construct new criteria from observed data. Methods. Data were …

Objective The 1987 American College of Rheumatology (ACR; formerly, the American
Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized …

Background Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment
of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour …

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objectives The provisional criteria of the American College of Rheumatology (ACR) 2010
and the 2011 self-report modification for survey and clinical research are widely used for …

Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting …

Objective. To develop a fibromyalgia (FM) survey questionnaire for epidemiologic and clinical
studies using a modification of the 2010 American College of Rheumatology Preliminary …